3 ms·

As an owner of a rare "MS-like disease" aka MOGAD I cant wait. The point of this treatment is that if you know which protein is the trigger you can stop it. It'

by sputr 3y ago

As an owner of a rare "MS-like disease" aka MOGAD I cant wait. The point of this treatment is that if you know which protein is the trigger you can stop it. It's probably not a cure, but an even better alternative to the current treatments that all cause at least some side effects or are not entirely effective. I should note that I know of active phase 2 trials by other campanies for type 1 diabetes.

consp 3y ago
> I should note that I know of active phase 2 trials by other campanies for type 1 diabetes For those less informed and unfortunate owners of this malice, can you elaborate?
- sputr 3y ago
  Yeah, sorry, was on my phone. I've been following this company: http://imcyse.com/pipeline#type-1-diabetes http://imcyse.com/pipeline#type-1-diabetes First, disclaimer, I'm a patient (MOGAD), not a medical professional. As far as phases goes, as far as I understand it, phase 1 is safety, phase 2 is initial trial for efficacy. Quote from the website about Type 1 diabetes: > In Type 1 diabetes (T1D), the insulin-producing beta cells in the pancreas are destroyed through an autoimmune attack. The loss of beta cells leads to insulin insufficiency and hyperglycemia, with patients eventually requiring lifelong insulin therapy to maintain normal glycemic control. ... >IMCY-0098, a synthetic peptide based on insulin (one of the proteins to which the body begins to mount an aberrant immune response) is designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta cells. With early intervention, the pancreas’ ability to produce insulin may be preserved, enabling patients to manage the disease with minimal insulin injections and hopefully in some cases without the need for insulin at all. > In a Phase 1b study with 41 newly diagnosed patients, IMCY-0098, was found to be safe and well tolerated, with steady levels of C-peptides detected in some T1D patients up to 6 months following treatment, providing an encouraging signal for the Imotope™ platform. > IMCY-0098 is currently being investigated in a Phase 2 multicenter, randomized, double-blind, placebo-controlled, dose comparison study in patients with recent onset T1D. .... The study completed recruitment in March 2023 exceeding its recruitment target, with a total of 110 patients enrolled and randomized across 28 clinical sites in Europe, the United States and Australia. Efficacy proof-of-concept data from IMPACT is expected in Q1 2024.

by sputr 3y ago

consp 3y ago

> I should note that I know of active phase 2 trials by other campanies for type 1 diabetes For those less informed and unfortunate owners of this malice, can you elaborate?

sputr 3y ago
Yeah, sorry, was on my phone. I've been following this company: http://imcyse.com/pipeline#type-1-diabetes http://imcyse.com/pipeline#type-1-diabetes First, disclaimer, I'm a patient (MOGAD), not a medical professional. As far as phases goes, as far as I understand it, phase 1 is safety, phase 2 is initial trial for efficacy. Quote from the website about Type 1 diabetes: > In Type 1 diabetes (T1D), the insulin-producing beta cells in the pancreas are destroyed through an autoimmune attack. The loss of beta cells leads to insulin insufficiency and hyperglycemia, with patients eventually requiring lifelong insulin therapy to maintain normal glycemic control. ... >IMCY-0098, a synthetic peptide based on insulin (one of the proteins to which the body begins to mount an aberrant immune response) is designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta cells. With early intervention, the pancreas’ ability to produce insulin may be preserved, enabling patients to manage the disease with minimal insulin injections and hopefully in some cases without the need for insulin at all. > In a Phase 1b study with 41 newly diagnosed patients, IMCY-0098, was found to be safe and well tolerated, with steady levels of C-peptides detected in some T1D patients up to 6 months following treatment, providing an encouraging signal for the Imotope™ platform. > IMCY-0098 is currently being investigated in a Phase 2 multicenter, randomized, double-blind, placebo-controlled, dose comparison study in patients with recent onset T1D. .... The study completed recruitment in March 2023 exceeding its recruitment target, with a total of 110 patients enrolled and randomized across 28 clinical sites in Europe, the United States and Australia. Efficacy proof-of-concept data from IMPACT is expected in Q1 2024.